XCancer

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Description:

The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).

Sponsor:

Stanford University

Phase:

Phase 2

Contacts:

Grace Yi (CONTACT)

gracesyi@stanford.edu

650-723-1423

Roan C Raymundo, BS (CONTACT)

rcraymun@stanford.edu

(650) 721-4071

Fred Baik, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT05423197 - Click here to see study on

ClinicalTrials.gov

panitumumab

Isotope(s):
Target(s):
  • EGFR
Ligand Class: Antibodies
Chelator: DFO
Inclusion
  • Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.
  • Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
Exclusion

Exclusion Criteria Not Yet Provided